Ethanol and H2-receptor antagonists
✍ Scribed by Mack C. Mitchell; James J. Potter; Esteban Mezey; Helmut K. Seitz; Siegrid Veith; Peter Czygan; Johann Bösche; Bernd Simon; Burkhard Simon; Roland Gugler
- Publisher
- John Wiley and Sons
- Year
- 1985
- Tongue
- English
- Weight
- 252 KB
- Volume
- 5
- Category
- Article
- ISSN
- 0270-9139
No coin nor oath required. For personal study only.
✦ Synopsis
Since different forms of cytochrome P-450 are involved in the microsomal oxidation of ethanol and other substrates, such as aminopyrine, we were interested in whether cimetidine inhibits microsomal ethanol-oxidizing system (MEOS).
We determined the hepatic effect of cimetidine on the alcohol dehydrogenase and MEOS activities in uitro and on rates of ethanol elimination. Hepatic cytosol and microsomal fractions were obtained from male Sprague-Dawley rats and the determinations done as Dreviously described (1). The enzyme activities were assayed in the presence of cimetidine concentrations ranging between 0 and 5 mM. Cimetidine added in uitro did not alter the activities of either alcohol dehydrogenase or MEOS even at high ( 5 mM) concentrations. The inhibitory constant K, for the effects of cimetidine on other microsomal oxidations has been reported to be in the range of 0.1 to
📜 SIMILAR VOLUMES
The effect of four H2-receptor antagonists (cimetidine, burimamide, oxmetidine, and ranitidine) on antipyrine elimination was studied in the isolated perfused rat liver. The first three drugs are substituted imidazoles, whereas ranitidine contains a furanyl nucleus. Isolated livers were perfused usi
The influence of a 7-day medication of either cimetidine (1,000 mg per day) or ranitidine (300 mg per day) on serum ethanol concentrations after a single oral dose of ethanol (0.8 gm per kg body weight) was investigated in a randomized placebo-controlled study in eight male volunteers. Compared with
The aim of this study was to investigate the association between H 2 -receptor antagonists and acute pancreatitis. The automated database of the Medicines Monitoring Unit (MEMO) was used to carry out a case-control study, supplemented with information on possible confounding factors from hospital an